What is Glaucoma?
It is the irreversible damage suffered by the optic nerve as a result of a high pressure inside the eye. It is caused by a failure in the eye's natural drainage system, which, in order to function properly, must eliminate a fluid that is permanently produced inside it (it, called aqueous humor).
“Glaucoma: the silent thief of sight”
Unique Design
The IPM is a flat implant, not based on tubes, that works with the eye tissue to create a pressure-responsive relief valve, achieving a self-regulated outflow of aqueous humor.
How does it work?
With high pressure
- The aqueous humor lifts the tissue around the implant and flows through the intrascleral to ultimately form a subconjunctival bleb
- The size of the virtual space between the implant and the tissue can increase or decrease depending on fluctuations in intraocular pressure
With normal pressure
- Very little aqueous humor comes out and the eye is kept at the optimal pressure to function
The implant achieves a self-regulated outflow by allowing the formation of a natural relief valve that is activated by the pressure inside the eye
Publications
Explore featured publications related to ophthalmology innovation and glaucoma treatment.
Journal of Experimental Pharmacology
Livogrit Ameliorates Thioacetamide-Induced Liver Fibrosis and Dyslipidemia in Rat Model by Regulating Oxidative Stress and Hepatic Collagen Levels, in a Non-Mutagenic Manner
Featured article available for full reading in the original journal site.
IPM against common problems
of the surgical solutions
| Problem | Description | Advantages of the IPM |
|---|---|---|
| Flat chamber | Excessive loss of pressure in the eye due to too much outflow caused by the implant or the surgery. |
No flat chamber
|
| Obstructions | Components of the aqueous humor adhere to implants, clogging the tubes and reducing their drainage capacity. |
Less chance of obstructions
|
| Infections | Tubular implants or permanent connection surgeries allow external germs to travel inside the eye. |
Less possibility of infections
|
| Limited drainage capacity | Tubular implants have a fixed outlet size, therefore a limited outflow within the eye's normal pressure levels. |
Works for a wider range of pressures
|
| Bleeding / scarring | Bleeding caused during surgery can lead to scarring and this to obstruction of the implant. |
Reduced risk of bleeding/scarring
|
| Surgery, training, equipment | Most surgeries require special training, equipment, and instruments that are not available everywhere. |
Standard surgery
|
At a glance
Us
- • HQ in Lima - Peru
- • Subsidiary in Delaware - USA
- • Since 2014
- • 6 people
Patents
- • 33 granted
- • China, India, United States, Brazil, Japan, Mexico, Germany, Turkiye, United Kingdom, France, Italy, Thailand, Spain, Colombia, Korea, Peru, Netherlands, Chile, Romania, Belgium, Sweden, Portugal, Israel, Austria, Bulgaria, Denmark, Finland, Slovenia, Latvia, Lithuania, Estonia, Luxembourg, Malta.
- • 1 in process
Recognitions
- • Gold Medal with congratulations from the jury at the International Exhibition of Inventions in Geneva - Switzerland
- • 1st place Biotechnology & Medicine category at the National Contest of Inventions of Peru
- • Innovate Peru Fund for the "Validation of Innovation for Micro Companies"
Our Team
Mario Miranda
General Manager
Martín Miranda
Project Management
Juan Olivares
Financial Management
Gabriela Miranda
Administrative ManagementOur Vision
Reduce the number of blind people in the world
Our Mission
Making safe and efficient glaucoma treatment affordable and available for everybody
Timeline
-
2014
Research and Development
IPM prototypesCompassionate use in 13 patients -
2017
Patent Applications
14 offices covering major countries -
2019
Funding
Friends and FamilyInnovate Peru Fund -
2020
Pre-Clinical Trials
Testing and technical documentation on the implants -
2021
Clinical Trials
24 subjects over 1 year -
2026
Licensing
Licensing of the patents to a strategic partner to commercialize the product